These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2257861)

  • 1. Predictability and intraindividual variability of serum theophylline concentrations in patients with obstructive lung disease: 12-h versus 24-h dosing.
    Schmidlin O; Vozeh S; Keller B; Perruchoud A; Follath F
    Eur J Clin Pharmacol; 1990; 39(3):253-6. PubMed ID: 2257861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease.
    Martin RJ; Pak J
    Am Rev Respir Dis; 1992 Mar; 145(3):540-4. PubMed ID: 1546832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualization of theophylline dosage: a Bayesian method evaluated in patients with once-daily dosing.
    Martz W; Oellerich M; Schnabel D; Sybrecht GW
    Ther Drug Monit; 1991 Sep; 13(5):420-4. PubMed ID: 1957334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily dosing of a new ultrasustained-release theophylline preparation.
    Van den Brande P; Nys J; Tjandramaga TB; Verhelst F; Demedts M
    Respiration; 1987; 52(2):144-53. PubMed ID: 3671893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circadian variation in plasma theophylline concentrations during maintenance therapy with a sustained-release preparation in patients with obstructive airways disease.
    Taylor DR; Duffin D; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1984 Jul; 18(1):27-30. PubMed ID: 6743488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of theophylline on lung function and sleep in patients with severe chronic obstructive pulmonary disease].
    Li Y; Liu Y
    Zhonghua Jie He He Hu Xi Za Zhi; 1997 Oct; 20(5):294-8. PubMed ID: 10374456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theophylline steady-state pharmacokinetics: recent concepts and their application in chronotherapy of reactive airway diseases.
    Steinijans VW; Trautmann H; Johnson E; Beier W
    Chronobiol Int; 1987; 4(3):331-47. PubMed ID: 3315264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of two long-acting theophylline preparations in daily evening administration].
    Holzer R
    Wien Med Wochenschr; 1993; 143(2):37-42. PubMed ID: 8488685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interactions of theophylline and nifedipine].
    Luther R; Wichert H; Köhler E; Banditt P; Walther H
    Z Erkr Atmungsorgane; 1990; 174(2):97-103. PubMed ID: 2349818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.
    McKay SE; Howie CA; Thomson AH; Whiting B; Addis GJ
    Thorax; 1993 Mar; 48(3):227-32. PubMed ID: 8497820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unequal twice-daily, sustained-release theophylline dosing in chronic obstructive pulmonary disease.
    Bruguerolle B; Philip-Joet F; Parrel M; Arnaud A
    Chronobiol Int; 1987; 4(3):381-5. PubMed ID: 3315267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of erythromycin stearate on serum theophylline concentration in patients with chronic obstructive lung disease.
    Stults BM; Felice-Johnson J; Higbee MD; Hardigan K
    South Med J; 1983 Jun; 76(6):714-8. PubMed ID: 6857302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the bronchodilating effect of two doses of a sustained release theophylline.
    Prignot J; Delaunois L; Lulling J; Delwiche JP; Vandenplas F
    Respiration; 1984; 46(2):166-73. PubMed ID: 6436935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dosing time on the pharmacokinetics and pharmacodynamics of a 'once-a-day' sustained release theophylline preparation.
    Lamont H; Pauwels R; Van der Straeten M
    Br J Clin Pharmacol; 1987 Dec; 24(6):735-42. PubMed ID: 3440095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of once-daily Uniphyl tablets compared with twice-daily Theo-Dur tablets in elderly patients with chronic airflow obstruction.
    Rivington RN; Calcutt L; Hodder RV; Stewart JH; Aitken TL
    Am J Med; 1988 Jul; 85(1B):48-53. PubMed ID: 3041826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of theophylline in chronic obstructive lung disease.
    Umut S; Gemicioğlu B; Yildirim N; Barlas A; Ozüner Z
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):149-52. PubMed ID: 1592541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Time-related distribution of delayed-action theophylline in the treatment of chronic obstructive bronchopneumopathies].
    Philip-Joet F; Bruguerolle B; Parrel M; Vestri R; Arnaud A
    Presse Med; 1988 Feb; 17(5):193-6. PubMed ID: 2965374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Components of variability in serum theophylline concentrations during maintenance therapy with a sustained release formulation.
    Halkin H; Mazar A; Almog S; Schnaps Y
    Eur J Clin Pharmacol; 1982; 23(3):225-8. PubMed ID: 7173293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The arrhythmogenicity of theophylline. A multivariate analysis of clinical determinants.
    Bittar G; Friedman HS
    Chest; 1991 Jun; 99(6):1415-20. PubMed ID: 2036824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronotherapy of reversible airways disease with once-daily evening doses of a controlled-release theophylline preparation.
    Goldenheim PD; Schein LK
    Ann N Y Acad Sci; 1991; 618():490-503. PubMed ID: 2006803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.